Aclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up of A-101 45% Topical Solution for Potential Treatment of Common Warts
Aclaris Therapeutics, Inc. (ACRS)
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aclaristx.com
Company Research
Source: GlobeNewswire
Primary, secondary, and exploratory endpoints of Phase 2 trial met during 8-week treatment periodAfter treatment completed, greater improvement vs. placebo observed in 3-month post-treatment follow-up evaluationIf approved, A-101 45% would be the first FDA-approved treatment for common warts WAYNE, Pa., March 19, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) today announced positive results from the 3-month, post-treatment, follow-up evaluation period of its twice-weekly placebo-controlled trial (WART-203) of A-101 45% topical solution (A-101 45%), an investigational new drug consisting of a proprietary high-concentration hydrogen peroxide topical solution being developed as a prescription treatment for common warts (verruca vulgaris). As previously reported, A-101 45% met the trial endpoints related to reduction and clearance of common warts versus placebo during the initial 56-day treatment period. Over the 3-month post-treatment follow-up period, greater imp
Show less
Read more
Impact Snapshot
Event Time:
ACRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRS alerts
High impacting Aclaris Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRS
News
- Cryopyrin-Associated Periodic Syndrome Drug Pipeline Report 2024: Therapeutic Developments for Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics, and Mabpharm [Yahoo! Finance]Yahoo! Finance
- Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive OfficerPR Newswire
- Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock [Yahoo! Finance]Yahoo! Finance
- Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? [Yahoo! Finance]Yahoo! Finance
ACRS
Earnings
- 2/27/24 - Beat
ACRS
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- ACRS's page on the SEC website